MYCT1

Across TCGA pan-cancer cohorts, MYCT1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYCT1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MYCT1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MYCT1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SKCM, LIHC, and HNSC are the cancer types where MYCT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	1.000	0.708	<.001	19	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
HNSC	OS	Median	All	0.201	0.688	.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	III,IV	0.147	0.664	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYCT1–SKCM (DFS)

Open the SKCM breakdown →